U.S. pharma large copyright scrapped two experimental weight loss pills last yr—a after-everyday tablet, lotiglipron, because of elevated liver enzymes and also a 2 times-every day tablet, danuglipron, on account of solid side effects—but CEO Albert Bourla has claimed the company is set to “Participate in and earn” during the being overweig